---
document_datetime: 2025-12-02 05:47:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/alprolix.html
document_name: alprolix.html
version: success
processing_time: 0.1192367
conversion_datetime: 2025-12-26 09:25:00.546874
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Alprolix

[RSS](/en/individual-human-medicine.xml/66549)

##### Authorised

This medicine is authorised for use in the European Union

eftrenonacog alfa Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Alprolix](#news-on)
- [More information on Alprolix](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Alprolix. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Alprolix.

For practical information about using Alprolix, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Alprolix and what is it used for?

Alprolix is a medicine used to treat and prevent bleeding in patients with haemophilia B, an inherited bleeding disorder caused by lack of a clotting protein called factor IX. It can be used in patients of all ages.

Because the number of patients with haemophilia B is low, the disease is considered 'rare', and Alprolix was designated an 'orphan medicine' (a medicine used in rare diseases) on 8 June 2007.

Alprolix contains the active substance eftrenonacog alfa.

## How is Alprolix used?

Alprolix can only be obtained with a prescription and treatment should be under the supervision of a doctor who has experience in the treatment of haemophilia.

Alprolix is available as a powder and solvent that are mixed together to make a solution for injection into a vein. The dose and frequency of treatment depend on the patient's bodyweight and whether Alprolix is used to treat or prevent bleeding, as well as the severity of the patient's factor IX deficiency, the extent and location of the bleeding and the patient's age and health. For further information on how to use this medicine, see the summary of product characteristics (also part of the EPAR).

Patients or their carers may be able to inject Alprolix themselves at home once they have been trained appropriately. For full details, see the package leaflet.

## How does Alprolix work?

Patients with haemophilia B lack factor IX, a protein needed for normal clotting of the blood, and as a result, they bleed readily. The active substance in Alprolix, eftrenonacog alfa, works in the body in the same way as human factor IX. It replaces the missing factor IX, thereby helping the blood to clot and giving temporary control of bleeding.

## What benefits of Alprolix have been shown in studies?

Alprolix has been shown to be effective at both preventing and treating bleeding episodes in 2 main studies in patients with haemophilia B.

In the first study involving 123 adults and adolescents aged 12 years or above, patients given Alprolix as a weekly preventive treatment had around 3 bleeding episodes a year, patients given Alprolix as an every 10 days preventive treatment had around 2 bleeding episodes per year, and patients given Alprolix for treating bleedings on demand had around 18 bleeding episodes a year. In addition, when bleeding did occur, around 90% of bleeding episodes resolved with one injection of Alprolix.

In the second study in 30 children aged below 12 years, Alprolix was similarly effective: 2 bleeding episodes occurred per year on average and around 75% of bleeding episodes resolved with one injection.

## What are the risks associated with Alprolix?

Hypersensitivity (allergic) reactions are seen rarely with Alprolix and include: swelling, burning and stinging at the injection site, chills, flushing, itchy rash, headache, hives, low blood pressure, lethargy, nausea and vomiting, restlessness, a fast heartbeat, tightness of the chest and wheezing. In some cases these reactions can become severe.

Some patients taking factor IX medicines may develop inhibitors (antibodies) against factor IX, causing the medicine to stop working and resulting in a loss of bleeding control. Factor IX medicines can also potentially cause problems due to the formation of blood clots in the blood vessels.

For the full list of all side effects and restrictions with Alprolix, see the package leaflet.

## Why is Alprolix approved?

Studies show that Alprolix is effective at preventing and treating bleeding episodes in patients with haemophilia B and its safety is comparable to that of other factor IX products. The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that Alprolix's benefits are greater than its risks and recommended that it be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Alprolix?

A risk management plan has been developed to ensure that Alprolix is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Alprolix, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Alprolix

The European Commission granted a marketing authorisation valid throughout the European Union for Alprolix on 12 May 2016.

For more information about treatment with Alprolix, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Alprolix : EPAR - Summary for the public

Reference Number: EMA/171272/2016

English (EN) (75.56 KB - PDF)

**First published:** 25/05/2016

**Last updated:** 25/05/2016

[View](/en/documents/overview/alprolix-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-292)

български (BG) (100.57 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/bg/documents/overview/alprolix-epar-summary-public_bg.pdf)

español (ES) (75.4 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/es/documents/overview/alprolix-epar-summary-public_es.pdf)

čeština (CS) (101.64 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/cs/documents/overview/alprolix-epar-summary-public_cs.pdf)

dansk (DA) (74.89 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/da/documents/overview/alprolix-epar-summary-public_da.pdf)

Deutsch (DE) (76.57 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/de/documents/overview/alprolix-epar-summary-public_de.pdf)

eesti keel (ET) (74.26 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/et/documents/overview/alprolix-epar-summary-public_et.pdf)

ελληνικά (EL) (102.85 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/el/documents/overview/alprolix-epar-summary-public_el.pdf)

français (FR) (76.29 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/fr/documents/overview/alprolix-epar-summary-public_fr.pdf)

hrvatski (HR) (96.36 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/hr/documents/overview/alprolix-epar-summary-public_hr.pdf)

italiano (IT) (74.96 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/it/documents/overview/alprolix-epar-summary-public_it.pdf)

latviešu valoda (LV) (97.8 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/lv/documents/overview/alprolix-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (99.39 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/lt/documents/overview/alprolix-epar-summary-public_lt.pdf)

magyar (HU) (96.29 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/hu/documents/overview/alprolix-epar-summary-public_hu.pdf)

Malti (MT) (101.64 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/mt/documents/overview/alprolix-epar-summary-public_mt.pdf)

Nederlands (NL) (75.27 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/nl/documents/overview/alprolix-epar-summary-public_nl.pdf)

polski (PL) (101.21 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/pl/documents/overview/alprolix-epar-summary-public_pl.pdf)

português (PT) (75.97 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/pt/documents/overview/alprolix-epar-summary-public_pt.pdf)

română (RO) (97.64 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/ro/documents/overview/alprolix-epar-summary-public_ro.pdf)

slovenčina (SK) (95.04 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/sk/documents/overview/alprolix-epar-summary-public_sk.pdf)

slovenščina (SL) (94.42 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/sl/documents/overview/alprolix-epar-summary-public_sl.pdf)

Suomi (FI) (74.28 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/fi/documents/overview/alprolix-epar-summary-public_fi.pdf)

svenska (SV) (74.82 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/sv/documents/overview/alprolix-epar-summary-public_sv.pdf)

Alprolix : EPAR - Risk-management-plan summary

English (EN) (105.11 KB - PDF)

**First published:** 10/04/2019

**Last updated:** 04/11/2020

[View](/en/documents/rmp-summary/alprolix-epar-risk-management-plan-summary_en.pdf)

## Product information

Alprolix : EPAR - Product Information

English (EN) (534.48 KB - PDF)

**First published:** 25/05/2016

**Last updated:** 02/05/2025

[View](/en/documents/product-information/alprolix-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-134)

български (BG) (601.62 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/bg/documents/product-information/alprolix-epar-product-information_bg.pdf)

español (ES) (485.31 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/es/documents/product-information/alprolix-epar-product-information_es.pdf)

čeština (CS) (669.72 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/cs/documents/product-information/alprolix-epar-product-information_cs.pdf)

dansk (DA) (528.86 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/da/documents/product-information/alprolix-epar-product-information_da.pdf)

Deutsch (DE) (532.03 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/de/documents/product-information/alprolix-epar-product-information_de.pdf)

eesti keel (ET) (508.62 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/et/documents/product-information/alprolix-epar-product-information_et.pdf)

ελληνικά (EL) (618.39 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/el/documents/product-information/alprolix-epar-product-information_el.pdf)

français (FR) (600.39 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

24/07/2025

[View](/fr/documents/product-information/alprolix-epar-product-information_fr.pdf)

hrvatski (HR) (569.54 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/hr/documents/product-information/alprolix-epar-product-information_hr.pdf)

íslenska (IS) (519.44 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/is/documents/product-information/alprolix-epar-product-information_is.pdf)

italiano (IT) (566.25 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/it/documents/product-information/alprolix-epar-product-information_it.pdf)

latviešu valoda (LV) (588.5 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/lv/documents/product-information/alprolix-epar-product-information_lv.pdf)

lietuvių kalba (LT) (582.62 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/lt/documents/product-information/alprolix-epar-product-information_lt.pdf)

magyar (HU) (695.54 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

24/07/2025

[View](/hu/documents/product-information/alprolix-epar-product-information_hu.pdf)

Malti (MT) (646.49 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/mt/documents/product-information/alprolix-epar-product-information_mt.pdf)

Nederlands (NL) (523.1 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/nl/documents/product-information/alprolix-epar-product-information_nl.pdf)

norsk (NO) (520.55 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/no/documents/product-information/alprolix-epar-product-information_no.pdf)

polski (PL) (610.84 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/pl/documents/product-information/alprolix-epar-product-information_pl.pdf)

português (PT) (531.37 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/pt/documents/product-information/alprolix-epar-product-information_pt.pdf)

română (RO) (606.99 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/ro/documents/product-information/alprolix-epar-product-information_ro.pdf)

slovenčina (SK) (617.92 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/sk/documents/product-information/alprolix-epar-product-information_sk.pdf)

slovenščina (SL) (571.28 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/sl/documents/product-information/alprolix-epar-product-information_sl.pdf)

Suomi (FI) (521.23 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/fi/documents/product-information/alprolix-epar-product-information_fi.pdf)

svenska (SV) (532.63 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

02/05/2025

[View](/sv/documents/product-information/alprolix-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000262414 30/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Alprolix : EPAR - All Authorised presentations

English (EN) (25.11 KB - PDF)

**First published:** 25/05/2016

**Last updated:** 25/05/2016

[View](/en/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-819)

български (BG) (69.11 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/bg/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_bg.pdf)

español (ES) (27.27 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/es/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_es.pdf)

čeština (CS) (63.36 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/cs/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (28.52 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/da/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (28.45 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/de/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (26.61 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/et/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (68.44 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/el/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_el.pdf)

français (FR) (28.07 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/fr/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (63.71 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/hr/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (24.18 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/is/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_is.pdf)

italiano (IT) (26.37 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/it/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (63.11 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/lv/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (64.94 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/lt/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (63.44 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/hu/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (65.85 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/mt/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (27.06 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/nl/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (27.59 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/no/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_no.pdf)

polski (PL) (61.01 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/pl/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_pl.pdf)

português (PT) (30.14 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/pt/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_pt.pdf)

română (RO) (62.41 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/ro/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (64.41 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/sk/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (43.15 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/sl/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (28.27 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/fi/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (28.71 KB - PDF)

**First published:**

25/05/2016

**Last updated:**

25/05/2016

[View](/sv/documents/all-authorised-presentations/alprolix-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Alprolix Active substance eftrenonacog alfa International non-proprietary name (INN) or common name eftrenonacog alfa Therapeutic area (MeSH) Hemophilia B Anatomical therapeutic chemical (ATC) code B02BD04

### Pharmacotherapeutic group

- Vitamin K and other hemostatics
- Blood coagulation factors

### Therapeutic indication

Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

## Authorisation details

EMA product number EMEA/H/C/004142

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Swedish Orphan Biovitrum AB (publ)

SE-112 76 Stockholm

Marketing authorisation issued 12/05/2016 Revision 11

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Alprolix : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (144.2 KB - PDF)

**First published:** 02/05/2025

[View](/en/documents/procedural-steps-after/alprolix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Alprolix : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (153.7 KB - PDF)

**First published:** 24/11/2016

**Last updated:** 02/05/2025

[View](/en/documents/procedural-steps-after/alprolix-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Alprolix-H-C-PSUSA-00010499-202303 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/263695/2024

English (EN) (166.94 KB - PDF)

**First published:** 05/06/2024

[View](/en/documents/scientific-conclusion/alprolix-h-c-psusa-00010499-202303-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Alprolix-H-C-4142-P46-006 : EPAR - Assessment report

Adopted

Reference Number: EMA/562337/2020

English (EN) (2.39 MB - PDF)

**First published:** 10/03/2021

[View](/en/documents/variation-report/alprolix-h-c-4142-p46-006-epar-assessment-report_en.pdf)

Alprolix-H-C-4142-II-0029 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/562322/2020

English (EN) (717.27 KB - PDF)

**First published:** 10/03/2021

[View](/en/documents/variation-report/alprolix-h-c-4142-ii-0029-epar-assessment-report-variation_en.pdf)

Alprolix-H-C-4142-II-0021 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/210117/2019

English (EN) (1.56 MB - PDF)

**First published:** 10/04/2019

[View](/en/documents/variation-report/alprolix-h-c-4142-ii-0021-epar-assessment-report-variation_en.pdf)

Alprolix-H-C-PSUSA-00010499-201803 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/492734/2018

English (EN) (84.68 KB - PDF)

**First published:** 19/07/2018

**Last updated:** 19/07/2018

[View](/en/documents/scientific-conclusion/alprolix-h-c-psusa-00010499-201803-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Alprolix : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/196953/2016

English (EN) (4.17 MB - PDF)

**First published:** 25/05/2016

**Last updated:** 25/05/2016

[View](/en/documents/assessment-report/alprolix-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Alprolix

Adopted

Reference Number: EMA/CHMP/83216/2016

English (EN) (67.75 KB - PDF)

**First published:** 26/02/2016

**Last updated:** 26/02/2016

[View](/en/documents/smop-initial/chmp-summary-opinion-alprolix_en.pdf)

#### News on Alprolix

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-february-2016) 26/02/2016

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/search?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-1=1=EMEAHC0041420000) (initial marketing authorisation)

#### More information on Alprolix

- [EU/3/07/453 - orphan designation for treatment of haemophilia B (congenital factor IX deficiency)](/en/medicines/human/orphan-designations/eu-3-07-453)
- [EMEA-000914-PIP01-10-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000914-pip01-10-m05)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 02/05/2025

## Share this page

[Back to top](#main-content)